Skip to content
Sunday 23 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,816.56
+0.64%
DAX
26,136.56
+0.59%
CAC 40
8,484.43
+0.37%
STOXX 50
6,462.22
+0.63%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Monday 25 February 2019 8:56 am  |  Updated:  Monday 03 June 2019 12:16 am

Hiscox profits treble as London market returns to growth

Insurer Hiscox announced its profits trebled last year as it returned to growth in its London market for the first time in three years.

The firm also revealed that it has completed its Brexit preparations and is ready for the UK to leave the EU “even if British politicians are not”.

The figures

Pre-tax profit was $137.4m (£105m) in the year to the end of December 2018, up from $39.7m the previous year, the Lloyd’s of London underwriter announced this morning. Profits were seven per cent ahead of the company's estimate.

Read more: Hiscox boss elected as alderman in Canada election

Gross premiums grew 15 per cent from $3286m to $3778m in the period. 

Meanwhile, the insurer's Brexit preparations have cost Hiscox an estimated $15m in one off costs, most of which was incurred last year, and will continue to cost $2.4m a year.

Why it matters

The firm’s London market was the “standout performer” of the year as the business returned to growth and profit after three years of action to reduce or exit unprofitable activity. Since the end of 2016 the London team has exited $400m of “challenged business” and replaced it with stronger performing business.

The firm has established a presence in Luxemburg as part of its Brexit preparations, and will use Lloyd’s Brussels to ensure risks in the Eurozone which were previously placed with Lloyd’s of London.

What the company said

Hiscox chief executive Bronek Masojada said: “We have generated strong growth and good profits in a busy year for claims.

“The tough action we took in our London market business is paying off, and we are seeing some positive momentum in big-ticket lines, where rates, terms and conditions are improving.

“We are growing well in our chosen retail segments, and our small market shares mean the size of the opportunity in retail remains immense.

“We will continue to invest in our people, infrastructure and brand and maintain our focus on disciplined growth.”

Read more: Royal Mail, Kier Group and Thomas Cook set to lose out in FTSE reshuffle

What analysts said

Shore Capital Markets analyst Paul De'Ath said: "As we have seen with Hiscox’s peers, 2018 was a challenging year but 2019 and beyond look more positive, assuming there are not the same level of global catastrophe events seen over the last two years.

"The results are slightly ahead of expectations and should provide enough to give the shares a boost this morning, in our view."

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Brexit

Trending Articles

  • House prices in wealthy London boroughs fall by up to £300,000

  • Ratcliffe’s Ineos saves Runcorn plant

  • Amazon says it buys books in bulk to ‘improve products’

  • Mike Ashley’s Frasers offers to pay personal shoppers in Harvey Nichols takeover

  • As it happened: FTSE 100 rallies after JD Sports drags on blue chips; oil jumps again

More from Morning Wire

  • Hiscox finance chief: London’s AI adoption is too slow

    Opinion
    Paul Cooper, a man in a navy suit, gestures during a business meeting at a conference table.
  • Burnley axe main sponsor Finotive after just six weeks and promote Vertu to shirt

    Sport Business
    Smiling man in Burnley FC kit with Finotive One sponsor, arms outstretched, on a football pitch with stadium stands behind.
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Lord O’Neill declines job in Burnham government

    Economics
    Jim ONeill, economist and former Goldman Sachs chairman, sitting on a yellow sofa in front of large windows.
  • Wizz Air profit wiped out by rising fuel prices

    Markets
    The CEO of Wizz Air received a huge bonus in 2024.
  • North Sea is not competitive, says BP boss days after exit

    Markets
    British Petroleum BP forecourt with fuel pumps and company signage visible in a business setting, highlighting energy serv...
  • ‘Hard work ahead’: Diageo shares soar as Drastic Dave’s cost savings lift investor spirits

    Markets
    Diageo is expected to reveal a drop in profits for the past year
  • Aviva profits jump following Direct Line acquisition

    Insurance
    Aviva's deal to buy Direct Line was agreed in March
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook